RCM-1

Research use only, not for human use.

RCM-1 is an inhibitor of FOXM1. RCM-1 inhibits cellular proliferation via the increasing duration of cell cycle and mitosis in human and mouse cancer cell lines in vitro. RCM-1 inhibits colony formation of cancer cells in vitro in a dose-dependent manner. RCM-1 inhibits the migration of cancer cells in vitro in a dose-dependent manner.

RCM-1 is an inhibitor of FOXM1. RCM-1 inhibits cellular proliferation via the increasing duration of cell cycle and mitosis in human and mouse cancer cell lines in vitro. RCM-1 inhibits colony formation of cancer cells in vitro in a dose-dependent manner. RCM-1 inhibits the migration of cancer cells in vitro in a dose-dependent manner. RCM-1 inhibits the initiation as well as the growth of cancer cell colonies in vitro. Treatment with RCM-1 increases the duration of mitosis and cell cycle in the cancer cell lines.RCM-1 decreases the B 16-FlO tumor growth as compared to the Vehicle -treated group. RCM-1 treatment decreases tumor cell proliferation and increased apoptosis in B16-FlO melanoma tumors. RCM-1 treatment reduces the growth of the human H2122 lung adenocarcinoma in mice. RCM-1 treatment reduces tumor cell proliferation and increases apoptosis in Rd76-9 rhabdomyosarcoma tumors. RCM-1 treatment decreases the growth of Rd76-9 rhabdomyosarcomas in mice. The RCM-1-treated Rd76-9 tumors display reduced FOXM1 staining and decreased expression of proliferation-specific markers Ki67 and PH3. Cleaved caspase staining is increased in the RCM-1 treated tumors, indicating an increase in apoptosis. RCM-1 treatment reduces the growth of B16-FlO melanoma tumors in mice.

RCM-1 blocks the nuclear localization and increased the proteasomal degradation of FOXM1, a transcription factor critical for the differentiation of goblet cells from airway progenitor cells. In cultured airway epithelial cells, RCM-1 reduces IL-13 and STAT6 signaling and prevented the expression of the STAT6 target genes Spdef and Foxa3, which are key transcriptional regulators of goblet cell differentiation.

RCM-1 reduces airway resistance, increased lung compliance, and decreased proinflammatory cytokine production in mice exposed to the house dust mite and interleukin-13 (IL-13), which triggers goblet cell metaplasia. In mice, RCM-1 reduces IL-13 and STAT6 signaling and prevented the expression of the STAT6 target genes Spdef and Foxa3.

——

Others

Other Targets

FOXM1

——

——

339163-65-4

424.58

C20H12N2OS4

>98% (HPLC)

DMSO:16.67 mg/mL (39.26 mM; Need ultrasonic)

O=C(CSc1nc(cc(-c2cccs2)c1C#N)-c1cccs1)c1cccs1

——

(-20℃)

With Ice Pack

≥ 2 years